KMCSHIL.BO · BSE
KMC SPECIALITY HOSPITALS (INDI
₹150.4
-4.14% (-₹6.5)
Prev. close
₹156.9
Volume
1
As of
BSE · may be slightly delayed · 16:00 IST
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About KMC SPECIALITY HOSPITALS (INDI
KMC Speciality Hospitals (India) Limited provides medical and healthcare services in India. The company offers healthcare services in the areas of anesthesiology, arthroscopy, breast clinic, cardiology, critical care, dermatology, dental maxillofacial, diabetology, emergency and urgent care, endocrinology, family clinic, fertility centre, general surgery, general medicine, geriatrics, gastroenterology, heart and lung transplant, interventional radiology, infectious diseases, laboratory services, lung centre, liver disease, neurology, and neurosurgery; and nephrology and urology science, as well as ENT, head, and neck surgery; and kidney, liver, and bone marrow transplant. It also provides healthcare services in the areas of ophthalmology, obstetrics and gynecology, orthopaedics, oncology, paediatrics and neonatology, plastic surgery, psychiatry, pulmonology, rheumatology, spine surgery, transfusion medicine, sports medicine, and vascular surgery. The company was formerly known as Seahorse Hospital Limited and changed its name to KMC Speciality Hospitals (India) Limited in October 2008. KMC Speciality Hospitals (India) Limited was incorporated in 1982 and is based in Trichy, India. KMC Speciality Hospitals (India) Limited is a subsidiary of Sri Kauvery Medical Care (India) Limited.
Details
Sector
Healthcare
Industry
Medical Care Facilities
CEO
Dr. Sundararaj Chandra Kumar M.D.
Headquarters
Trichy
Employees
1,695
Website
kauveryhospital.comExchange
View on BSE ↗Key stats
Market cap
₹2,452.80 Cr
P/E ratio (TTM)
43.7
EPS (TTM)
₹3.44
Beta (1Y · daily vs NIFTY 50)
0.73
Beta (5Y · monthly vs NIFTY 50)
0.35
Shares float
3.53 Cr
EPS · quarter ended Jun 2026
₹1.02
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.6% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹102.64 Cr | ₹136.07 Cr | ₹154.89 Cr | ₹175.42 Cr | ₹229.31 Cr | ₹302.79 Cr | |
| EBITDA | ₹25.16 Cr | ₹39.32 Cr | ₹44.44 Cr | ₹50.95 Cr | ₹59.97 Cr | ₹93.00 Cr |
| ₹12.78 Cr | ₹23.73 Cr | ₹26.69 Cr | ₹30.38 Cr | ₹21.43 Cr | ₹46.73 Cr | |
| Diluted EPS | ₹0.78 | ₹1.45 | ₹1.64 | ₹1.86 | ₹1.31 | ₹2.87 |
Depreciation & amortisation, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹181.65 Cr | ₹263.72 Cr | ₹286.00 Cr | ₹332.12 Cr | |
| — | — | ₹49.94 Cr | ₹81.82 Cr | ₹89.45 Cr | ₹83.68 Cr | |
| Stockholders' equity | — | — | ₹113.50 Cr | ₹143.58 Cr | ₹164.33 Cr | ₹210.43 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹32.33 Cr | ₹38.42 Cr | ₹57.58 Cr | ₹79.10 Cr | |
| Investing cash flow | — | — | ₹-47.99 Cr | ₹-55.91 Cr | ₹-50.94 Cr | ₹-16.93 Cr |
| — | — | ₹15.84 Cr | ₹20.50 Cr | ₹-2.30 Cr | ₹-21.34 Cr | |
| Capital expenditure | — | — | ₹-44.11 Cr | ₹-75.27 Cr | ₹-63.88 Cr | ₹-16.64 Cr |
| End cash position | — | — | ₹1.84 Cr | ₹4.85 Cr | ₹9.19 Cr | ₹50.02 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| KMC SPECIALITY HOSPITALS (INDI | ₹2,546.57 Cr | ₹132.8 | 45.5 | 12.10 | 22.2% | 0.40 | +32.0% | +99.0% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 29
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
1 index
Weight is BSE’s own published index weight. Indices without weight data are listed without one, in alphabetical order after the weighted ones.